Knockdown of TSPEAR-AS2 effectively inhibits breast cancer cell growth and aerobic glycolysis, suggesting that targeting the C-myc/TSPEAR-AS2/GLUT1 axis has important potential research value for the treatment of breast cancer [58, 59]. This evidence concerns the gene SLC2A1 and breast cancer.